Acquiring Company
EQT Private Equity
Acquired Company
QIAGEN
Description
On October 21, EQT agreed to acquire QIAGEN N.V. in a cash transaction offering 46.50 euros per share. The transaction is expected to close in mid-2027, subject to regulatory clearances and other conditions. The tender offer has not yet started, so the change of ownership is not yet complete.
Who to call at EQT Private Equity, and when
When EQT Private Equity changes hands, the new owners review vendors, systems and leadership. That is when the door opens.
- An alert the day EQT Private Equity raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at EQT Private Equity, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at EQT Private Equity. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment EQT Private Equity makes an acquisition, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
Frequently asked
Who acquired QIAGEN?
QIAGEN was acquired by EQT Private Equity. The deal was reported on October 21, 2026. EQT, Advent, and KKR & Co. are private equity firms that invest in various sectors, focusing on value creation through operational improvements and strategic growth. EQT Private Equity is privately held and operates in Financial Services.
When did EQT Private Equity acquire QIAGEN?
EQT Private Equity's acquisition of QIAGEN was reported on October 21, 2026. On October 21, EQT agreed to acquire QIAGEN N.V. in a cash transaction offering 46.50 euros per share. The transaction is expected to close in mid-2027, subject to regulatory clearances and other conditions. Fundz records the date the transaction was first publicly reported, sourced from filings and company announcements.
What does QIAGEN do?
QIAGEN N.V., a Netherlands-based holding company, is the leading global provider of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. It is privately held, operating in Biotechnology.
This company was part of an acquisition. Fundz tracks who bought whom, and who to call on both sides.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.